ProCE Banner Activity

LIBRETTO-531: Phase III Trial of Selpercatinib vs Cabozantinib or Vandetanib in Patients With Advanced RET-Mutant Medullary Thyroid Cancer

Conference Coverage
Slideset

First-line selpercatinib improves PFS and time to treatment failure vs cabozantinib or vandetanib in an interim analysis of the phase III LIBRETTO-531 trial in patients with advanced RET-mutated medullary thyroid cancer.

Released: October 25, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc